Using GenScript’s NeoPre™ bioinformatics algorithm for difficult neoantigen peptide synthesis

Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, lenght, and charge. Leveraging extensive peptide synthesis experience, Genscript has developed NeoPre, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone. NeoPre can then recomment the most efficient approach to successfully synthesizing peptides using one of GenScript's many synthesis platforms. This case study highlights how NeoPre identifies synthesis difficulty and review sucessful cases of dificult neoantigen peptide synthesis.